Can a Two-Drug combo outsmart pancreatic cancer?

NCT ID NCT07756281

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of the combination and to look for early signs that it may help control the cancer. Participants receive the drugs in repeating cycles and undergo regular blood tests, scans, and exams to monitor side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SNV1521 (an oral PARP inhibitor) combined with daraxonrasib (an oral RAS inhibitor)
What this could lead to
If this combination proves safe and shows activity, it could lead to a new treatment option for advanced pancreatic cancer, a disease with few effective therapies.
What could go wrong
This is an early-phase, small trial focused on safety and dosing, so it may not show clear benefit. The drug combination could cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ACINAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.